Lynn Yamamoto
About Lynn Yamamoto
Lynn Yamamoto is an Associate Director at Tenaya Therapeutics, with a strong background in molecular toxicology and microbiology. She has held various scientific roles at companies such as Second Genome Inc., Pfizer-Rinat, and Fountain Therapeutics over her career.
Current Role at Tenaya Therapeutics
Lynn Yamamoto serves as the Associate Director at Tenaya Therapeutics, a position she has held since 2023. In this role, she contributes to the development of innovative therapies aimed at treating heart disease. Her responsibilities include overseeing research initiatives and collaborating with cross-functional teams to advance the company's therapeutic pipeline.
Professional Experience at Second Genome Inc.
Lynn Yamamoto has extensive experience at Second Genome Inc., where she held multiple roles from 2015 to 2021. She began as a Scientist and progressed to Scientist 2, and then to Senior Scientist. In 2021, she was appointed as Director and Head of IBD Research, a role she held until 2022. Her work focused on advancing research in inflammatory bowel disease (IBD) during her tenure.
Previous Role at Fountain Therapeutics
Before joining Tenaya Therapeutics, Lynn Yamamoto worked as the Director of Translational Biology at Fountain Therapeutics from 2022 to 2023. In this role, she was responsible for bridging the gap between preclinical research and clinical applications, ensuring that scientific discoveries translated effectively into potential therapies.
Post-Doctoral Research at Pfizer-Rinat
Lynn Yamamoto completed her post-doctoral research at Pfizer-Rinat in South San Francisco from 2011 to 2015. During this four-year period, she focused on advancing scientific knowledge and contributing to drug development processes within the pharmaceutical industry.
Educational Background at UCLA
Lynn Yamamoto earned her Doctor of Philosophy (Ph.D.) in Molecular Toxicology from UCLA, completing her studies from 2003 to 2009. She also holds a Bachelor of Science (B.S.) degree in Microbiology and Molecular Genetics from the same institution. Her educational background provides a strong foundation for her work in the biotechnology and pharmaceutical sectors.